Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
NCT00113802 · Gilead Sciences · PHASE2 · terminated · last registry update 2021-08-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low accrual” | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD22 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-04-06Results posted on the registry: SWOG Cancer Research Network, cyclophosphamide + vincristine sulfate (NCT01925131)
- 2022-01-28Also stopped (withdrawn): Roswell Park Cancer Institute, Inotuzumab Ozogamicin + Vincristine Sulfate Liposome (NCT03851081)
- 2021-08-18Also stopped (withdrawn): Gilead Sciences, Veltuzumab and 90Y-Epratuzumab Tetraxetan + 90Y-epratuzumab tetraxetan (NCT01101581)
- 2021-08-16Also stopped (terminated): Gilead Sciences, hLL2 (epratuzumab) (NCT00054834)
- 2021-04-13Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03488225)
- 2021-04-12Results posted on the registry: M.D. Anderson Cancer Center, Inotuzumab Ozogamicin (NCT03094611)
- 2021-04-12Also stopped (terminated): M.D. Anderson Cancer Center, Inotuzumab Ozogamicin (NCT03094611)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision